Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

IL-7-induced proliferation of peripheral Th17 cells is impaired in HAART-controlled HIV infection.

Côté SC, Stilla A, Burke Schinkel SC, Berthoud TK, Angel JB.

AIDS. 2019 May 1;33(6):985-991. doi: 10.1097/QAD.0000000000002164.

PMID:
30946152
2.

A Balanced Proinflammatory and Regulatory Cytokine Signature in Young African Children Is Associated With Lower Risk of Clinical Malaria.

Dobaño C, Nhabomba AJ, Manaca MN, Berthoud T, Aguilar R, Quintó L, Barbosa A, Rodríguez MH, Jiménez A, Groves PL, Santano R, Bassat Q, Aponte JJ, Guinovart C, Doolan DL, Alonso PL.

Clin Infect Dis. 2019 Aug 16;69(5):820-828. doi: 10.1093/cid/ciy934.

PMID:
30380038
3.

Cord Blood IL-12 Confers Protection to Clinical Malaria in Early Childhood Life.

Song Y, Aguilar R, Guo J, Manaca MN, Nhabomba A, Berthoud TK, Khoo SK, Wiertsema S, Barbosa A, Quintó L, Laing IA, Mayor A, Guinovart C, Alonso PL, LeSouëf PN, Dobaño C, Zhang GB.

Sci Rep. 2018 Jul 18;8(1):10860. doi: 10.1038/s41598-018-29179-y.

4.

High production of pro-inflammatory cytokines by maternal blood mononuclear cells is associated with reduced maternal malaria but increased cord blood infection.

Dobaño C, Berthoud T, Manaca MN, Nhabomba A, Guinovart C, Aguilar R, Barbosa A, Groves P, Rodríguez MH, Jimenez A, Quimice LM, Aponte JJ, Ordi J, Doolan DL, Mayor A, Alonso PL.

Malar J. 2018 May 10;17(1):177. doi: 10.1186/s12936-018-2317-2.

5.

IL-23 signaling in Th17 cells is inhibited by HIV infection and is not restored by HAART: Implications for persistent immune activation.

Fernandes JR, Berthoud TK, Kumar A, Angel JB.

PLoS One. 2017 Nov 1;12(11):e0186823. doi: 10.1371/journal.pone.0186823. eCollection 2017.

6.

Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.

Dunachie S, Berthoud T, Hill AV, Fletcher HA.

Vaccine. 2015 Sep 29;33(40):5321-31. doi: 10.1016/j.vaccine.2015.07.087. Epub 2015 Aug 7.

7.

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.

Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, Gilbert SC.

Mol Ther. 2014 Mar;22(3):668-674. doi: 10.1038/mt.2013.284. Epub 2013 Dec 30.

8.

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.

Antrobus RD, Berthoud TK, Mullarkey CE, Hoschler K, Coughlan L, Zambon M, Hill AV, Gilbert SC.

Mol Ther. 2014 Jan;22(1):233-8. doi: 10.1038/mt.2013.162. Epub 2013 Jul 8.

9.

Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.

Powell TJ, Peng Y, Berthoud TK, Blais ME, Lillie PJ, Hill AV, Rowland-Jones SL, McMichael AJ, Gilbert SC, Dong T.

PLoS One. 2013 May 3;8(5):e62778. doi: 10.1371/journal.pone.0062778. Print 2013.

10.

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.

Antrobus RD, Lillie PJ, Berthoud TK, Spencer AJ, McLaren JE, Ladell K, Lambe T, Milicic A, Price DA, Hill AV, Gilbert SC.

PLoS One. 2012;7(10):e48322. doi: 10.1371/journal.pone.0048322. Epub 2012 Oct 31.

11.

Interleukin-10 (IL-10) polymorphisms are associated with IL-10 production and clinical malaria in young children.

Zhang G, Manaca MN, McNamara-Smith M, Mayor A, Nhabomba A, Berthoud TK, Khoo SK, Wiertsema S, Aguilar R, Barbosa A, Quintó L, Candelaria P, Schultz EN, Hayden CM, Goldblatt J, Guinovart C, Alonso PL, Lesouëf PN, Dobaño C.

Infect Immun. 2012 Jul;80(7):2316-22. doi: 10.1128/IAI.00261-12. Epub 2012 May 7.

12.

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.

Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC.

Clin Infect Dis. 2012 Jul;55(1):19-25. doi: 10.1093/cid/cis327. Epub 2012 Mar 22. Erratum in: Clin Infect Dis. 2019 Jun 18;69(1):195.

13.

Comparison of commercial kits to measure cytokine responses to Plasmodium falciparum by multiplex microsphere suspension array technology.

Berthoud TK, Manaca MN, Quelhas D, Aguilar R, Guinovart C, Puyol L, Barbosa A, Alonso PL, Dobaño C.

Malar J. 2011 May 9;10:115. doi: 10.1186/1475-2875-10-115.

14.

A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.

Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, Biswas S, Poulton I, Prieur E, Correa S, Rowland R, Lang T, Williams J, Gilbert SC, Sinden RE, Todryk S, Hill AV.

Vaccine. 2011 Oct 6;29(43):7514-22. doi: 10.1016/j.vaccine.2011.03.083. Epub 2011 Apr 16.

15.

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC.

Clin Infect Dis. 2011 Jan 1;52(1):1-7. doi: 10.1093/cid/ciq015.

16.

MIG and the regulatory cytokines IL-10 and TGF-β1 correlate with malaria vaccine immunogenicity and efficacy.

Dunachie SJ, Berthoud T, Keating SM, Hill AV, Fletcher HA.

PLoS One. 2010 Sep 3;5(9):e12557. doi: 10.1371/journal.pone.0012557.

17.

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.

Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, Colloca S, Cortese R, Hill AV.

Infect Immun. 2010 Jan;78(1):145-53. doi: 10.1128/IAI.00740-09. Epub 2009 Oct 26. Erratum in: Infect Immun. 2011 May;79(5):2131.

18.

Comparing human T cell and NK cell responses in viral-based malaria vaccine trials.

Berthoud TK, Fletcher H, Porter D, Thompson F, Hill AV, Todryk SM.

Vaccine. 2009 Dec 10;28(1):21-7. doi: 10.1016/j.vaccine.2009.09.132. Epub 2009 Oct 17.

PMID:
19837090
19.

The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming.

Todryk SM, Pathan AA, Keating S, Porter DW, Berthoud T, Thompson F, Klenerman P, Hill AV.

Immunology. 2009 Sep;128(1):83-91. doi: 10.1111/j.1365-2567.2009.03073.x. Erratum in: Immunology. 2011 Apr;132(4):589.

20.

MIG (CXCL9) is a more sensitive measure than IFN-gamma of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines.

Berthoud TK, Dunachie SJ, Todryk S, Hill AV, Fletcher HA.

J Immunol Methods. 2009 Jan 1;340(1):33-41. doi: 10.1016/j.jim.2008.09.021. Epub 2008 Oct 24. Erratum in: J Immunol Methods. 2011 May 31;368(1-2):84.

21.

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.

Fletcher HA, Pathan AA, Berthoud TK, Dunachie SJ, Whelan KT, Alder NC, Sander CR, Hill AV, McShane H.

Vaccine. 2008 Sep 26;26(41):5269-75. doi: 10.1016/j.vaccine.2008.07.040. Epub 2008 Aug 3.

22.

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei.

Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, Gao G, Ertl HC, Wilson JC, Hill AV.

Eur J Immunol. 2008 Mar;38(3):732-41. doi: 10.1002/eji.200737672. Erratum in: Eur J Immunol. 2011 May;41(5):1501.

23.

Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.

Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, Todryk S, Poulton I, Correa S, Hutchings C, Berthoud T, Dunachie S, Andrews L, Williams JL, Sinden R, Gilbert SC, Pluschke G, Zurbriggen R, Hill AV.

PLoS One. 2008 Jan 30;3(1):e1493. doi: 10.1371/journal.pone.0001493. Erratum in: PLoS One. 2011;6(2). doi: 10.1371/annotation/419b2f36-d46f-4f8a-8ffb-7fd2bfb33aa6.

24.

Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area.

Imoukhuede EB, Andrews L, Milligan P, Berthoud T, Bojang K, Nwakanma D, Ismaili J, Buckee C, Njie F, Keita S, Sowe M, Lang T, Gilbert SC, Greenwood BM, Hill AV.

Am J Trop Med Hyg. 2007 Mar;76(3):486-93.

25.

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, Andersen RF, Bejon P, Goonetilleke N, Poulton I, Webster DP, Butcher G, Watkins K, Sinden RE, Levine GL, Richie TL, Schneider J, Kaslow D, Gilbert SC, Carucci DJ, Hill AV.

Infect Immun. 2006 Oct;74(10):5933-42.

26.

Early gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-naïve and malaria-exposed individuals.

Bejon P, Keating S, Mwacharo J, Kai OK, Dunachie S, Walther M, Berthoud T, Lang T, Epstein J, Carucci D, Moris P, Cohen J, Gilbert SC, Peshu N, Marsh K, Hill AV.

Infect Immun. 2006 Nov;74(11):6331-8. Epub 2006 Sep 11.

27.

Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.

Imoukhuede EB, Berthoud T, Milligan P, Bojang K, Ismaili J, Keating S, Nwakanma D, Keita S, Njie F, Sowe M, Todryk S, Laidlaw SM, Skinner MA, Lang T, Gilbert S, Greenwood BM, Hill AV.

Vaccine. 2006 Oct 30;24(42-43):6526-33. Epub 2006 Jun 28.

PMID:
16842888
28.

Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.

Walther M, Thompson FM, Dunachie S, Keating S, Todryk S, Berthoud T, Andrews L, Andersen RF, Moore A, Gilbert SC, Poulton I, Dubovsky F, Tierney E, Correa S, Huntcooke A, Butcher G, Williams J, Sinden RE, Hill AV.

Infect Immun. 2006 May;74(5):2706-16.

29.

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

Dunachie SJ, Walther M, Vuola JM, Webster DP, Keating SM, Berthoud T, Andrews L, Bejon P, Poulton I, Butcher G, Watkins K, Sinden RE, Leach A, Moris P, Tornieporth N, Schneider J, Dubovsky F, Tierney E, Williams J, Heppner DG Jr, Gilbert SC, Cohen J, Hill AV.

Vaccine. 2006 Apr 5;24(15):2850-9. Epub 2006 Jan 6.

PMID:
16434127
30.

Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria.

Keating SM, Bejon P, Berthoud T, Vuola JM, Todryk S, Webster DP, Dunachie SJ, Moorthy VS, McConkey SJ, Gilbert SC, Hill AV.

J Immunol. 2005 Nov 1;175(9):5675-80.

31.

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.

Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, Keating SM, Berthoud T, Webster D, McShane H, Hill AV.

Vaccine. 2006 May 22;24(21):4554-61. Epub 2005 Aug 24. Review.

PMID:
16150517
32.

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.

Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, Bejon P, Butcher G, Sinden R, Skinner MA, Gilbert SC, Hill AV.

Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4836-41. Epub 2005 Mar 21.

33.

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.

Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, Hill AV.

J Immunol. 2005 Jan 1;174(1):449-55.

34.

Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.

Walther M, Dunachie S, Keating S, Vuola JM, Berthoud T, Schmidt A, Maier C, Andrews L, Andersen RF, Gilbert S, Poulton I, Webster D, Dubovsky F, Tierney E, Sarpotdar P, Correa S, Huntcooke A, Butcher G, Williams J, Sinden RE, Thornton GB, Hill AV.

Vaccine. 2005 Jan 4;23(7):857-64.

PMID:
15603885

Supplemental Content

Loading ...
Support Center